Pharmacological update on new infusion drugs.
Ongoing clinical research and development of new infusion medications can challenge the infusion specialist's knowledge base in daily practice. This article reviews new and soon-to-be marketed infusion drugs, with an emphasis on biopharmaceuticals. The author also discusses mechanisms of action, drug interactions, side effects, and infusion specialist interventions for safe administration of these medications.
Wilder
G L
GL
Home Infusion Service at Stanford University Medical Center, USA. glwilder@aol.com
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D001682:Biological Availability; D001702:Biopharmaceutics; D001709:Biotechnology / Q000639:trends; D000077336:Caspofungin; D054714:Echinocandins; D006207:Half-Life; D006801:Humans; D007262:Infusions, Intravenous; D055666:Lipopeptides; D010455:Peptides; D010456:Peptides, Cyclic
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D000970:Antineoplastic Agents; D054714:Echinocandins; D055666:Lipopeptides; D010455:Peptides; D010456:Peptides, Cyclic; D000077336:Caspofungin